Banking on Fostamatinib, Rigel Seeks to Raise $130M

By Catherine ShafferStaff Writer

Wednesday, October 3, 2012

A public offering worth $130 million will extend Rigel Pharmaceuticals Inc.'s cash runway through potential approval of its lead product, fostamatinib. The South San Francisco-based company will offer about 13.7 million shares of common stock at $9.50 per share, to close on or about Oct. 9.